Maria E. Verdugo

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Michael Hallek, William G. Wierda et al. · Clinical Cancer Research · 2018 · 161 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Relationship between venetoclax exposure, rituximab coadministration, and progression‐free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy

Kevin J. Freise, Aksana K. Jones, Rajeev Menon et al. · Hematological Oncology · 2016 · 42 citations

Pharmacy, Immunology, Pharmacotherapy +17

Age-Related Increase in Activity of Specific Lysosomal Enzymes in the Human Retinal Pigment Epithelium

Maria E. Verdugo, Jharna Ray · Experimental Eye Research · 1997 · 26 citations · Full text

Life Sciences, Biochemistry, Cell Biology +15

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J. Freise et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 26 citations

Medicine, Oncology, Pharmacotherapy +11

Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.

Jeffrey A. Jones, William G. Wierda, Michael Y. Choi et al. · Journal of Clinical Oncology · 2016 · 22 citations

Medicine, Pharmacology, Pharmacotherapy +13